Novartis Unit Hits Roche With HIV Patent Suit

Law360, New York (November 21, 2007, 12:00 AM EST) -- Novartis Vaccines and Diagnostics Inc. has launched a legal battle alleging Hoffmann-La Roche Inc.’s HIV fusion inhibitor, Fuzeon, infringes one of the Swiss drug maker’s patents.

In a complaint filed Monday in the U.S. District Court for the Eastern District of Texas, Novartis claimed that defendants Hoffmann-La Roche, Roche Laboratories Inc., Roche Colorado Corp., Trimeris Inc. and F. Hoffmann-La Roche Ltd. infringe its U.S. Patent No. 7,285,271.

The patent, titled “Antigenic composition comprising an HIV gag or env polypeptide,” was issued to Novartis in October, the...
To view the full article, register now.